Henan Lingrui Pharmaceutical Co Ltd (600285) - Net Assets

Latest as of March 2026: CN¥3.69 Billion CNY ≈ $539.28 Million USD

Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has net assets worth CN¥3.69 Billion CNY (≈ $539.28 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.97 Billion ≈ $872.97 Million USD) and total liabilities (CN¥2.28 Billion ≈ $333.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Henan Lingrui Pharmaceutical Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥3.69 Billion
% of Total Assets	61.78%
Annual Growth Rate	17.92%
5-Year Change	50.26%
10-Year Change	62.67%
Growth Volatility	102.51

Henan Lingrui Pharmaceutical Co Ltd - Net Assets Trend (1997–2025)

This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Henan Lingrui Pharmaceutical Co Ltd (600285) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Henan Lingrui Pharmaceutical Co Ltd (1997–2025)

The table below shows the annual net assets of Henan Lingrui Pharmaceutical Co Ltd from 1997 to 2025. For live valuation and market cap data, see 600285 company net worth.

Year	Net Assets	Change
2025-12-31	CN¥3.44 Billion ≈ $502.78 Million	+11.55%
2024-12-31	CN¥3.08 Billion ≈ $450.74 Million	+10.06%
2023-12-31	CN¥2.80 Billion ≈ $409.54 Million	+9.39%
2022-12-31	CN¥2.56 Billion ≈ $374.38 Million	+11.89%
2021-12-31	CN¥2.29 Billion ≈ $334.60 Million	-1.53%
2020-12-31	CN¥2.32 Billion ≈ $339.80 Million	+4.58%
2019-12-31	CN¥2.22 Billion ≈ $324.92 Million	+6.01%
2018-12-31	CN¥2.09 Billion ≈ $306.49 Million	-4.97%
2017-12-31	CN¥2.20 Billion ≈ $322.52 Million	+4.35%
2016-12-31	CN¥2.11 Billion ≈ $309.08 Million	+22.51%
2015-12-31	CN¥1.72 Billion ≈ $252.28 Million	+10.46%
2014-12-31	CN¥1.56 Billion ≈ $228.39 Million	+58.47%
2013-12-31	CN¥984.89 Million ≈ $144.12 Million	+41.31%
2012-12-31	CN¥696.97 Million ≈ $101.99 Million	+1.89%
2011-12-31	CN¥684.01 Million ≈ $100.09 Million	-3.62%
2010-12-31	CN¥709.69 Million ≈ $103.85 Million	+9.91%
2009-12-31	CN¥645.69 Million ≈ $94.48 Million	+17.46%
2008-12-31	CN¥549.72 Million ≈ $80.44 Million	-5.10%
2007-12-31	CN¥579.24 Million ≈ $84.76 Million	+19.02%
2006-12-31	CN¥486.67 Million ≈ $71.21 Million	+1.43%
2005-12-31	CN¥479.80 Million ≈ $70.21 Million	+2.20%
2004-12-31	CN¥469.45 Million ≈ $68.70 Million	+3.93%
2003-12-31	CN¥451.69 Million ≈ $66.10 Million	+8.39%
2002-12-31	CN¥416.74 Million ≈ $60.98 Million	+3.72%
2001-12-31	CN¥401.79 Million ≈ $58.79 Million	-1.63%
2000-12-31	CN¥408.46 Million ≈ $59.77 Million	+557.93%
1999-12-31	CN¥62.08 Million ≈ $9.08 Million	+24.53%
1998-12-31	CN¥49.85 Million ≈ $7.30 Million	+46.73%
1997-12-31	CN¥33.98 Million ≈ $4.97 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Henan Lingrui Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 7951.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥2.15 Billion	63.29%
Other Components	CN¥1.25 Billion	36.71%
Total Equity	CN¥3.40 Billion	100.00%

Henan Lingrui Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Neinor Homes SLU MC:HOME	$1.67 Billion
Chongqing Three Gorges Water Conservancy and Electric Power Co Ltd SHG:600116	$1.67 Billion
Three's Company Media Group Co Ltd SHG:605168	$1.67 Billion
Shenzhen Bromake New Material Co. Ltd. A SHE:301387	$1.67 Billion
Pebblebrook Hotel Trust NYSE:PEB	$1.67 Billion
CBIZ Inc NYSE:CBZ	$1.67 Billion
Aether Industries Limited NSE:AETHER	$1.67 Billion
Zhejiang DiAn Diagnostics Co SHE:300244	$1.67 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Henan Lingrui Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,072,526,287 to 3,400,583,879, a change of 328,057,592 (10.7%).
Net income of 759,503,033 contributed positively to equity growth.
Dividend payments of 511,285,618 reduced retained earnings.
Other factors increased equity by 79,840,177.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥759.50 Million	+22.33%
Dividends Paid	CN¥511.29 Million	-15.04%
Other Changes	CN¥79.84 Million	+2.35%
Total Change	CN¥-	10.68%

Book Value vs Market Value Analysis

This analysis compares Henan Lingrui Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.36x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 268.15x to 3.36x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1997-12-31	CN¥0.08	CN¥20.12	x
1998-12-31	CN¥0.11	CN¥20.12	x
1999-12-31	CN¥0.14	CN¥20.12	x
2000-12-31	CN¥0.90	CN¥20.12	x
2001-12-31	CN¥0.89	CN¥20.12	x
2002-12-31	CN¥1.84	CN¥20.12	x
2003-12-31	CN¥1.92	CN¥20.12	x
2004-12-31	CN¥1.95	CN¥20.12	x
2005-12-31	CN¥2.01	CN¥20.12	x
2006-12-31	CN¥1.01	CN¥20.12	x
2007-12-31	CN¥1.25	CN¥20.12	x
2008-12-31	CN¥1.12	CN¥20.12	x
2009-12-31	CN¥1.43	CN¥20.12	x
2010-12-31	CN¥1.52	CN¥20.12	x
2011-12-31	CN¥1.49	CN¥20.12	x
2012-12-31	CN¥1.49	CN¥20.12	x
2013-12-31	CN¥1.84	CN¥20.12	x
2014-12-31	CN¥2.84	CN¥20.12	x
2015-12-31	CN¥3.23	CN¥20.12	x
2016-12-31	CN¥3.62	CN¥20.12	x
2017-12-31	CN¥3.71	CN¥20.12	x
2018-12-31	CN¥3.53	CN¥20.12	x
2019-12-31	CN¥3.89	CN¥20.12	x
2020-12-31	CN¥4.07	CN¥20.12	x
2021-12-31	CN¥4.02	CN¥20.12	x
2022-12-31	CN¥4.49	CN¥20.12	x
2023-12-31	CN¥4.93	CN¥20.12	x
2024-12-31	CN¥5.45	CN¥20.12	x
2025-12-31	CN¥6.00	CN¥20.12	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Henan Lingrui Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 22.33%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 19.71%
• Asset Turnover: 0.68x
• Equity Multiplier: 1.66x
Recent ROE (22.33%) is above the historical average (13.97%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1997	67.21%	31.05%	0.82x	2.64x	CN¥19.44 Million
1998	48.05%	22.18%	0.86x	2.52x	CN¥18.97 Million
1999	34.71%	20.72%	0.59x	2.82x	CN¥15.34 Million
2000	5.77%	18.02%	0.25x	1.26x	CN¥-17.29 Million
2001	6.25%	14.58%	0.31x	1.39x	CN¥-15.07 Million
2002	3.15%	6.90%	0.27x	1.68x	CN¥-28.40 Million
2003	3.28%	6.00%	0.32x	1.72x	CN¥-29.03 Million
2004	3.49%	4.51%	0.41x	1.88x	CN¥-28.67 Million
2005	4.07%	4.62%	0.46x	1.92x	CN¥-26.89 Million
2006	2.82%	3.28%	0.45x	1.93x	CN¥-32.74 Million
2007	12.41%	13.36%	0.55x	1.68x	CN¥13.50 Million
2008	1.98%	2.48%	0.44x	1.83x	CN¥-42.51 Million
2009	4.67%	6.33%	0.45x	1.63x	CN¥-33.40 Million
2010	7.02%	12.74%	0.32x	1.73x	CN¥-20.58 Million
2011	4.48%	6.65%	0.37x	1.81x	CN¥-36.71 Million
2012	6.25%	7.54%	0.43x	1.91x	CN¥-25.47 Million
2013	10.89%	15.34%	0.42x	1.70x	CN¥8.64 Million
2014	4.94%	9.22%	0.33x	1.60x	CN¥-78.18 Million
2015	7.73%	12.16%	0.40x	1.59x	CN¥-38.70 Million
2016	16.57%	24.02%	0.48x	1.43x	CN¥137.06 Million
2017	9.99%	11.75%	0.56x	1.52x	CN¥-318.61K
2018	11.68%	11.85%	0.66x	1.49x	CN¥35.05 Million
2019	13.32%	13.65%	0.65x	1.50x	CN¥73.45 Million
2020	14.07%	13.96%	0.67x	1.50x	CN¥94.22 Million
2021	15.86%	13.42%	0.71x	1.66x	CN¥133.64 Million
2022	18.24%	15.50%	0.69x	1.70x	CN¥210.21 Million
2023	20.35%	17.16%	0.69x	1.71x	CN¥289.01 Million
2024	23.52%	20.64%	0.70x	1.63x	CN¥415.30 Million
2025	22.33%	19.71%	0.68x	1.66x	CN¥419.44 Million

Industry Comparison

This section compares Henan Lingrui Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,041,443,343
Average return on equity (ROE) among peers: 10.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Henan Lingrui Pharmaceutical Co Ltd (600285)	CN¥3.69 Billion	67.21%	0.62x	$1.67 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$971.04 Million	5.41%	3.98x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.33 Billion	6.10%	1.68x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$8.39 Billion	22.09%	0.19x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$1.42 Billion	23.64%	1.01x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$445.29 Million	14.73%	0.90x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$347.80 Million	3.58%	0.72x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$905.53 Million	2.15%	1.95x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$22.44 Billion	6.25%	0.15x	$3.00 Billion

About Henan Lingrui Pharmaceutical Co Ltd

SHG:600285 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.67 Billion

CN¥11.41 Billion CNY

Market Cap Rank

#6943 Global

#1560 in China

Share Price

CN¥20.12

Change (1 day)

-1.61%

52-Week Range

CN¥20.12 - CN¥24.46

All Time High

CN¥26.75